ODAC Approves MRD End Point in Multiple Myeloma Trials
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.
Investigators analyzed data from the Center for International Blood and Marrow Transplant Research who underwent autologous or allogeneic transplants.
FDA issued a safety warning that fluoroquinolone antibiotic use has been associated with aortic aneurysms and dissection of aortic aneurysms. Health care professionals should avoid…
ESC Heart Failure is the open access journal of the ESC Heart Failure Association, dedicated to the advancement of knowledge in the field of heart…
كنت بغطي القداس الرسمي لاحتفالات عيد القيامة بالكاتدرائية المرقسية بالعباسية وبعد ماخلصت ونازل تقريبا الساعة ١٢ بالليل وسمعت صوت الطبلة دي في كنيسة فرعية تحت…
Jonas Vingegaard says he will “do everything” to return to full fitness in time for the Tour de France after returning to road cycling for…
Chinese leader jabs the West as he prepares to arrive in Belgrade.
Caitlin Costello, MD, discusses the evolution of personalized treatment strategies for newly diagnosed multiple myeloma, comparing past and current treatment landscapes.
AbstractPopulation aging is one of the most important demographic transformations of our time. Increasing the “health span”—the proportion of life spent in good health—is a…
May 6, 2024 — SMT (Sahajanand Medical Technologies), a leading medical device company at the forefront of innovative patient care in the cardiovascular segment has announced a…